TScan publishes ALLOHA Cohort C Phase 1 presentation for TSC-101 TCR-T therapy in post-transplant AML, ALL and MDS

TScan Therapeutics, Inc.

TScan Therapeutics, Inc.

TCRX

0.00
  • TScan outlined Phase 1 ALLOHA Cohort C data for TSC-101, supporting a planned pivotal study launch in Q2 2026.
  • Long-term relapse-free survival favored TSC-101: 100% (2/2) at 3 years, 71% (5/7) at 2 years, 71% (12/17) at 1 year.
  • Control-arm relapse-free survival: 0% (0/3) at 3 years, 43% (3/7) at 2 years, 54% (7/13) at 1 year.
  • Cohort C used a commercial-ready process, cutting manufacturing time to 12 days from 17 days; 14 patients treated.
  • Cash balance USD 128.1 million as of March 31, 2026; management said this funds operations into H2 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TScan Therapeutics Inc. published the original content used to generate this news brief on June 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.